Showing 2271-2280 of 4063 results for "".
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Viatris Acquires Oyster Point Pharmahttps://modernod.com/news/viatris-acquires-oyster-point-pharma/2481230/Viatris, a global health care company, announced it is acquiring Oyster Point Pharma, maker of Tyrvaya nasal spray, for $11 per share in cash, plus contingent payments up to $2 per share based on the achievement of specified performance targets. The acquisition of Oyster Point
- Kinarus Therapeutics Provides Strategic Updatehttps://modernod.com/news/kinarus-therapeutics-provides-strategic-update/2481226/Kinarus Therapeutics reiterated its plans to focus on clinical trials in wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis, and to refocus its capital resources and financing efforts to drive these programs. Following the discontinuation of the phase 2 KINETIC
- Verana Health to Present Findings of Studies Using AAO IRIS Registry Data to Advance Insights into Real World Outcomes in Treating AMDhttps://modernod.com/news/verana-health-to-present-findings-of-studies-using-aao-iris-registry-data-to-advance-insights-into-real-world-outcomes-in-treating-amd/2481222/During The Retina Society’s 55th Annual Scientific Meeting Nov. 2-5, Verana Health will present findings on two studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy)
- Ocuphire Announces Peer-Reviewed Publication for Nyxol and Strategic Partnership with ASOAhttps://modernod.com/news/ocuphire-announces-peer-reviewed-publication-for-nyxol-and-strategic-partnership-with-asoa/2481215/Ocuphire Pharma announced that the positive results in night vision disturbances (NVD) patients from its earlier and first phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology. <
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30